ESR1 and breast cancer: As a confirmation, solvent exposure in early life, <36 years, induced a more evident increase of ER-positive/PR-negative tumors with respect to lifetime exposure [14], and only solvent exposure occurring before and in combination with the pregnancy proliferative changes demonstrated an influencing role in the development of ER-positive breast cancer types [16].